191 related articles for article (PubMed ID: 28776320)
1. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
2. 'New Medicine Service': supporting adherence in people starting a new medication for a long-term condition: 26-week follow-up of a pragmatic randomised controlled trial.
Elliott RA; Boyd MJ; Tanajewski L; Barber N; Gkountouras G; Avery AJ; Mehta R; Davies JE; Salema NE; Craig C; Latif A; Waring J; Chuter A
BMJ Qual Saf; 2020 Apr; 29(4):286-295. PubMed ID: 31732700
[TBL] [Abstract][Full Text] [Related]
3. Protocol for the New Medicine Service Study: a randomized controlled trial and economic evaluation with qualitative appraisal comparing the effectiveness and cost effectiveness of the New Medicine Service in community pharmacies in England.
Boyd M; Waring J; Barber N; Mehta R; Chuter A; Avery AJ; Salema NE; Davies J; Latif A; Tanajewski L; Elliott RA
Trials; 2013 Dec; 14():411. PubMed ID: 24289059
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).
Rubio-Valera M; Bosmans J; Fernández A; Peñarrubia-María M; March M; Travé P; Bellón JA; Serrano-Blanco A
PLoS One; 2013; 8(8):e70588. PubMed ID: 23950967
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis.
Taylor RS; Sadler S; Dalal HM; Warren FC; Jolly K; Davis RC; Doherty P; Miles J; Greaves C; Wingham J; Hillsdon M; Abraham C; Frost J; Singh S; Hayward C; Eyre V; Paul K; Lang CC; Smith K
Eur J Prev Cardiol; 2019 Aug; 26(12):1252-1261. PubMed ID: 30884975
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of two interventions to promote physical activity in a multiethnic population at high risk of diabetes: an economic evaluation of the 48-month PROPELS randomized controlled trial.
Heathcote LE; Pollard DJ; Brennan A; Davies MJ; Eborall H; Edwardson CL; Gillett M; Gray LJ; Griffin SJ; Hardeman W; Henson J; Khunti K; Sharp S; Sutton S; Yates T
BMJ Open Diabetes Res Care; 2024 Mar; 12(2):. PubMed ID: 38471669
[TBL] [Abstract][Full Text] [Related]
7. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial.
Peels DA; Hoogenveen RR; Feenstra TL; Golsteijn RH; Bolman C; Mudde AN; Wendel-Vos GC; de Vries H; Lechner L
BMC Public Health; 2014 Oct; 14():1099. PubMed ID: 25342517
[TBL] [Abstract][Full Text] [Related]
8. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Noble SM; Garfield K; Lane JA; Metcalfe C; Davis M; Walsh EI; Martin RM; Turner EL; Peters TJ; Thorn JC; Mason M; Bollina P; Catto JWF; Doherty A; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Rosario DJ; Rowe E; Oxley J; Staffurth J; Neal DE; Hamdy FC; Donovan JL
Br J Cancer; 2020 Sep; 123(7):1063-1070. PubMed ID: 32669672
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson's: an economic evaluation alongside a randomised controlled trial.
Xin Y; Ashburn A; Pickering RM; Seymour KC; Hulbert S; Fitton C; Kunkel D; Marian I; Roberts HC; Lamb SE; Goodwin VA; Rochester L; McIntosh E;
BMC Neurol; 2020 Aug; 20(1):295. PubMed ID: 32781987
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation.
Kruger J; Brennan A; Strong M; Thomas C; Norman P; Epton T
BMC Public Health; 2014 Sep; 14():1011. PubMed ID: 25262372
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Additional Preoperative Telephone Call to Increase Surgical Preparedness: Analysis of a Randomized Clinical Trial.
Halder GE; Guo F; Harvie H; White AB; Caldwell L; Giles DL; Bilagi D; Rogers RG
Int Urogynecol J; 2024 Mar; 35(3):527-536. PubMed ID: 38189853
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy.
Valverde-Merino MI; Martinez-Martinez F; Garcia-Mochon L; Benrimoj SI; Malet-Larrea A; Perez-Escamilla B; Zarzuelo MJ; Torres-Robles A; Gastelurrutia MA; Varas-Doval R; Peiro Zorrilla T; Garcia-Cardenas V
Patient Prefer Adherence; 2021; 15():2363-2376. PubMed ID: 34729007
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings.
RESPECT Trial Team
Br J Gen Pract; 2010 Jan; 60(570):e20-7. PubMed ID: 20040164
[TBL] [Abstract][Full Text] [Related]
14. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis.
Avery AJ; Rodgers S; Cantrill JA; Armstrong S; Cresswell K; Eden M; Elliott RA; Howard R; Kendrick D; Morris CJ; Prescott RJ; Swanwick G; Franklin M; Putman K; Boyd M; Sheikh A
Lancet; 2012 Apr; 379(9823):1310-9. PubMed ID: 22357106
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Laramée P; Brodtkorb TH; Rahhali N; Knight C; Barbosa C; François C; Toumi M; Daeppen JB; Rehm J
BMJ Open; 2014 Sep; 4(9):e005376. PubMed ID: 25227627
[TBL] [Abstract][Full Text] [Related]
16. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.
van Boven JF; Tommelein E; Boussery K; Mehuys E; Vegter S; Brusselle GG; Rutten-van Mölken MP; Postma MJ
Respir Res; 2014 Jun; 15(1):66. PubMed ID: 24929799
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.
Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; Bellows BK; Derington CG; Philip S; Steg G; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
J Am Heart Assoc; 2024 Jan; 13(1):e032413. PubMed ID: 38156550
[TBL] [Abstract][Full Text] [Related]
18. Modelled cost-effectiveness analysis of the Support and Treatment After Replacement (STAR) care pathway for chronic pain after total knee replacement compared with usual care.
Cole S; Noble S; Gooberman-Hill R; Pinedo-Villanueva R
Cost Eff Resour Alloc; 2024 Apr; 22(1):28. PubMed ID: 38605347
[TBL] [Abstract][Full Text] [Related]
19. A Trial-Based Cost-Utility Analysis of a Medication Optimization Intervention Versus Standard Care in Older Adults.
Robinson EG; Gyllensten H; Johansen JS; Havnes K; Granas AG; Bergmo TS; Småbrekke L; Garcia BH; Halvorsen KH
Drugs Aging; 2023 Dec; 40(12):1143-1155. PubMed ID: 37991657
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.
Ito K; Shrank WH; Avorn J; Patrick AR; Brennan TA; Antman EM; Choudhry NK
Health Serv Res; 2012 Dec; 47(6):2097-117. PubMed ID: 22998129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
